Abhishek Maiti, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase II study comparing outcomes of older acute myeloid leukemia (AML) patients receiving DEC10-VEN vs. intense chemotherapy, overall and after stratification by ‘fitness’ for intense chemotherapy using a validated treatment-related mortality score. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).